Lantern Pharma Inc - LTRN STOCK NEWS

Lantern Pharma (NASDAQ: LTRN), an AI-focused company developing cancer therapies, announced its participation in the upcoming ThinkEquity Conference. The presentation is scheduled for Wednesday, October 30, 2024, at 10:30 a.m. ET and will take place at the Mandarin Oriental in New York, NY. The company's management will be available for one-on-one meetings during the conference. The event can be accessed through provided webcast and registration links, offering investors an opportunity to learn about Lantern's innovative approach to oncology drug discovery and development.

Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology drug development company, announced two public webinars in October. The first, on October 28th, features CEO Panna Sharma discussing AI's role in developing therapies for brain and childhood cancers. The second, on October 30th, hosts Actuate Therapeutics' COO Andrew Mazar, highlighting how Lantern's AI platform accelerated the development of Actuate's drug candidate, Elragllusib.

The webinars will showcase RADR®, Lantern's AI platform, and its impact on advancing their portfolio and collaborators' work. Lantern will detail how big data and AI are leveraged to develop LP-184 and LP-284, currently in Phase 1 trials. The company will also discuss their blood-brain-barrier penetrability algorithm, important for LP-184's development in CNS cancer indications, including glioblastoma.

Lantern Pharma has received four Rare Pediatric Disease Designations and the FDA's Fast Track Designation for glioblastoma, underlining their progress in addressing critical unmet needs in oncology.

Lantern Pharma's investigational drug-candidate, LP-184, has received Fast Track Designation from the FDA for the treatment of Glioblastoma (GBM). This designation is designed to expedite FDA review of important new drugs for serious conditions with unmet medical needs. GBM affects over 13,000 U.S. adults annually and approximately 300,000 globally. LP-184, to be developed as STAR-001 by Starlight Therapeutics (a Lantern Pharma subsidiary), has the potential to be the first new GBM drug in over 20 years.

LP-184 is currently in a Phase 1A clinical trial evaluating its safety and tolerability in various solid tumors, including GBM. The drug was optimized using Lantern's AI platform, RADR®, which has over 100 billion data points and aids in cancer therapy discovery and development. A Phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025.

Lantern Pharma (NASDAQ: LTRN) has received three rare pediatric disease designations (RPDD) from the FDA for its drug candidate LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. This brings the total RPDDs for LP-184 to four, including a previous designation for atypical teratoid rhabdoid tumors. The efficacy of LP-184 was demonstrated through tumor regression and extended event-free survival in models developed by the NCI-supported Pediatric Preclinical Testing Program.

RPDDs can lead to Priority Review Vouchers upon FDA marketing approval, which can expedite future drug reviews or be sold for significant sums. LP-184 is currently in a Phase 1A clinical trial enrolling 50-60 patients across various solid tumors. Lantern Pharma aims to use AI and data-driven approaches to revolutionize cancer drug development, potentially reducing costs and accelerating timelines for new therapies.

Lantern Pharma (NASDAQ: LTRN) reported Q2 2024 financial results and business updates. Key highlights include:

1. Preliminary data from LP-300 Harmonic™ Trial showed 86% clinical benefit rate in initial 7-patient cohort.

2. Phase 1 trials for LP-184 and LP-284 progressing with no dose-limiting toxicities.

3. Launched AI-driven collaboration with Oregon Therapeutics for XCE853 development.

4. Starlight Therapeutics advancing Phase 1B/2 trial for STAR-001 in recurrent GBM.

5. Q2 2024 financials: $33.3M cash position, $3.9M R&D expenses, $1.5M G&A expenses, $4.96M net loss ($0.46 per share).

6. RADR® AI platform continues to expand in size and capabilities.

Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:

1. LP-184 potentiates anti-PD1 response in a mouse model of triple negative breast cancer (TNBC) resistant to immunotherapy.
2. It can transform 'cold' tumors into 'hot' tumors by modulating T cell activity and inducing replication stress response defects.
3. LP-184 reshapes the tumor microenvironment by reducing M2 macrophages associated with tumor drug resistance.
4. Combined with anti-PD1, LP-184 showed greater anti-tumor response than monotherapies in mouse TNBC tumors.

LP-184 is currently in a Phase 1 trial for advanced recurrent solid tumors. This research supports Lantern's AI-driven hypothesis on LP-184's potential to synergize with PD1 and PDL1 drugs, potentially improving cancer treatment outcomes.

Lantern Pharma (NASDAQ: LTRN) announced positive preliminary results from the Phase 2 HARMONIC™ clinical trial for LP-300 in never smokers with advanced non-small cell lung cancer (NSCLC). The initial patient cohort showed an 86% clinical benefit rate and a 43% objective response rate. Key findings include:

- 6 out of 7 patients experienced clinical benefit
- 3 patients showed partial responses with an average 51% tumor size reduction
- 3 patients had stable disease with an average 13% tumor size reduction
- No additional safety concerns or dose-limiting toxicities were observed
- Efficacy was seen regardless of prior treatments or tumor characteristics

The trial is now in the randomization and expansion phase, potentially enrolling up to 80 additional patients. Lantern Pharma aims to address the growing global need for therapies specifically approved for never-smoker NSCLC patients.

Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy company, has announced its second quarter 2024 operating and financial results webcast scheduled for August 8, 2024, at 4:30 p.m. ET. The company, which utilizes its proprietary RADR® AI and machine learning platform to develop targeted cancer therapies, will discuss Q2 results ending June 30, 2024. CEO Panna Sharma and other management team members will lead the call, providing insights on upcoming milestones, clinical trials, and AI platform developments. Interested parties can register for the webcast through the provided Zoom link, with a replay available on the company's investor relations website post-call.

Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirmation of PTGR1 as a important biomarker paves the way for further assay validation and eventual use in later-stage clinical trials. Studies have shown that incorporating biomarkers like PTGR1 can significantly enhance clinical trial success rates. LP-184, aimed at treating malignant gliomas, pancreatic cancer, and ATRT, holds both Orphan Drug and Rare Pediatric Disease designations from the FDA.